The Beneficial Effect of Adenophorae Radix on DSS‐induced Colitis in Mice

Ji?Wook Jung,Sa?Rang Oh,Eun?Mi Ahn,Eun?Ju Yang,Su?Jin Kim 대한의생명과학회 2013 Biomedical Science Letters Vol.19 No.3

Ulcerative colitis (UC) is an inflammatory bowel disease, which is a chronic gastrointestinal disorder. Adenophorae Radix (AR) has been used as a traditional medicine for various diseases including strengthening cardiac function, allaying a fever, and easing pain and cough. However, the regulatory effects of AR in intestinal inflammation are not yet understood. This study attempted to determine the effect of AR in dextran sulfate sodium (DSS) ? induced colitis in mice. The colitis mice were induced by drinking water containing 5% DSS for 7 days. The results showed that mice treated with DSS showed remarkable clinical signs, including weight loss, and reduced colon length. Administration of AR attenuated weight loss, colon shortening and inhibited the levels of interleukin (IL) ? 6 in DSS ? treated colon tissues. These results provide experimental evidence that AR might be a useful therapeutic medicine for patients with UC.

프로스타글란딘 E₁에칠에스테르의 외용 리오겔 제제 설계

양성운,이진교,이지은,김희규,박혜숙,김종석,최한곤,용철순,최영욱 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.2

External lyogels containing prostaglandin E₁ethyl ester(PGE₁-EE), a produrg of prostaglandin E₁(PGE₁) as a therapeutic agent for erectile dysfunction, were formulated to overcome the aqueous instability and enhance the percutaneous absorption. Lyogels of PGE₁-EE were prepared with ethanol (EtOH)/proplyene glycol (PG) cosolvent system as a vehicle, cineol as an enhancer, and hydroxypropylcellusose as a gelling agent. In vitro percutaneous absorption studies were performed to determine the rate of PGE₁ absorption through rat or hairless mouse skin. The permeability of PGE₁-EE lyogel with enhancer was 16-fold greater than that of lyogel without enhancer. Cosolvent produced 9-fold increase in percutaneous absorption. Pharmacodynamic effects of lyogels were evaluated in mature male cats in terms of intracavernosal pressure (ICP). Lyogles containing 0.01% of PGE₁-EE showed higher ICP compared to intraurethral preparation of PGE₁(1%) and enhancer-free control lyogel. The shelf-life (t_(10%) of lyogel at refrigerated condition (4℃) was calculated as 928 days, which is 4.2 times longer than that of control hydrogel. As a result, PGE₁-EE was formulated successfully to a lyogel system with a selective enhancer and cosolvent system for the topical delivery of PGE₁.

소뇌 출혈을 동반한 침입성 부비동 아스페르길루스증 1예

양현덕,박성욱,손일홍,이지용,석승한,조광호,이성수 圓光大學校 醫科學硏究所 2003 圓光醫科學 Vol.18 No.2

도시거주자의 혈중 카드뮴 농도와 간 및 신장 기능과의 상관성 평가

김호현,임영욱,임종한,양지연,신동천 한국환경독성학회 2003 환경독성보건학회지 Vol.18 No.1

The possibility that liver and kidney function is adversely affected by current levels of environmental exposure to cadmium (Cd) as investigated in adult men and women in the general population in Seoul. From February to August in 2001, blood and morning spot urine samples were collected from 136 not occupationally exposed group (age range 20~75 years) at 4 survey sites throughout Seoul. Liver and kidney function parameters in serum and urine were examined by conventional methods. The questionnaire included factors, i.e. sex, age, smoking, alcohol, diet habit etc. The geometric mean values for Cd in blood (Cd-B) were 1.43 μg/l. It seemed prudent to conclude that liver and kidney function as not disturbed by the current environmental exposure to Cd in study.

부산, 울산, 경남지역 직업병감시체계에서 나타난 수지진동증후근의 역학적 특성

최영희,유철인,이지호,이충렬,이헌,김영욱,채창호,고상백,김은아,이유진,김양호 大韓産業醫學會 2003 대한직업환경의학회지 Vol.15 No.3

목적: 국내에서도 국소진동에 의한 수지진동증후군이 다수 있을 것으로 추정하나 최근에 이에 대한 보고가 적어 부·울·경 직업병감시체계를 통하여 수지진동증후군에 대한 환례를 수집하여 이의 역학적 특성을 밝히고자 본 연구를 실시하였다. 방법: 2001년 44월부터 2002년 12월까지 부산, 울산, 경남지역에 있는 종합병원 9곳을 통하여 특수 건강진단과 산업의학과 외래를 방문한 근로자를 대상으로 진동폭로에 대한 설문조사를 실시하고 이들중에서 수지진동으로 인한 증상을 호소하는 근로자는 이학적 검사와 Stockholm workshop scale을 이용하여 수지진동증후군이 있는지 평가하였다. 결과: 남자 188명, 여자 4명 등 총 192례의 수진진동증후군이 의심되는 환례를 수집하였으며, 업종별로는 조선업에 종사하는 근로자들이 가장 많았다. 국소진동의 주된 폭로원은 그라인더가 가장 많았으며, 혈관장해로 인한 증상보다 감각신경성 장해로 인한 증상을 많이 호소하였다. 결론: 전국적으로 조선업종의 그라인더 사용자를 중심으로 많은 수의 수지진동증후군의 환자가 있을 것으로 추정되며, 이들에 대한 예방대책을 마련하기 위하여 전국규모의 정확한 유병률 조사 및 실태파악이 필요한 것으로 판단된다. Objects: The objectives of this study were to estimate the epidemiologic characteristics of hand-arm vibration syndrome (HAVS) due to occupational exposure of hand transmitted vibration and to identify the occupations and industries where such exposures arises, and the main sources of exposure. Methods: In April 2001 the Busan, Ulsan, and Kyung-Nam Province occupational disease surveillance system was established to measure the incidence and prevalence of work-relatd HAVS and other occipational diseases in these Korean provinces. Occupational physicians of nine hospitals in Busan, Ulsan, and Kyung-nam Province were involved in this project between April 2001 and November 2002. Physicians collected information through questionnaires and interviews. Information gathered included age, occupation, types of vibration tools used and presence of subkective symptoms such as vibration-induced white finger (VWF), numbness and tingling. Results: A total 192 cases were reported with 188 males and 4 females. The shipbuilding industry was the most common type of industry and grinders were the most common source of exposire. Symptoms of neurological disorder were more common than those of vascular disprder. Conclusions: The authors concluded that exposure to hand transmitted vibration is common and that HAVS is one of the most common occupational diseases in Korea. However, the range and extent of hand transmitted vibration and the overall prevalence of HAVS in Korea is still unknown. More extensive research on this syndrome in order to priorite necessary preventive measures is required.

[Colorectal] Single-port Laparoscopic (SPL) Versus Single-port Robotic (SPR) Right Hemicolectomy; Postoperative Outcome

Ji Ah Yang,Ji Ha Lim,Seong Hyeon Yun,Woo Yong Lee,Hee Cheol Kim,Yong Beom Cho,Jung Wook Huh,Yoon Ah Park,Jung Kyong Shin 대한외과학회 2021 대한외과학회 학술대회 초록집 Vol.2021 No.11

Differential Regulation of ErbB2 Expression by cAMP-Dependent Protein Kinase in Tamoxifen-Resistant Breast Cancer Cells

Yang, Ji-Won,Kim, Mi-Ra,kim, Hyung-Gyoon,Kim, Sang-Kyum,Jeong, Hye-Gwang,Kang, Keon-Wook 대한약학회 2008 Archives of Pharmacal Research Vol.31 No.3

Acquired resistance to tamoxifen (TAM) is a serious therapeutic problem in breast cancer patients, and Her-2/ErbB2 expression is associated with decreased sensitivity to TAM. We previously reported that cAMP-dependent protein kinase (PKA)-mediated activator protein-2 (AP-2) activation was responsible for the expression of Her-2/ErbB2 in p53-inactivated mammary epithelial cells (Yang et al., 2006). In the present study, we tested the hypothesis that PKA plays a role in the expression of ErbB2 in tamoxifen-resistant breast cancer cells. Treatment with H-89, a specific PKA inhibitor, suppressed 4-hydroxytamoxifen-induced ErbB2 expression in control MCF-7 cells. In contrast, PKA inhibition by H-89 or cAMP-dependent protein kinase inhibitor $I{\gamma}$ overexpression increased the expression levels of ErbB2 in TAM-resistant MCF-7 (TAMR-MCF-7) cells. Transcriptional regulation of the erbB2 gene depends on two transcription factors, AP-2 and polyomavirus enhancer activator3 (PEA3). H-89 decreased nuclear or total levels of PEA3 in TAMR-MCF-7 cells. Chromatin immunoprecipitation assay results revealed that H-89 treatment reduced PEA3 binding to the proximal Ets binding site of the erbB2 gene promoter. Reporter gene analyses using human erbB2 gene promoter supported the critical role of PEA3 in the overexpression of ErbB2 in TAMR-MCF-7 cells treated with H-89. This deregulated PKA signaling cascades required for the ErbB2 expression may be important for the differential response of TAM-resistant breast cancer cells to EGF/ErbB2 stimuli.

Thematic Poster : TP-74 ; Initiation of Anti-TNF Therapy Within 3 Weeks of LTBI Treatment in Patients with Immune-Mediated Inflammatory Diseases

( Ji Young Yang ),( Kyung Wook Jo ),( Seok Chan Hong ),( Bin Yoo ),( Chang Keun Lee ),( Yong Gil Kim ),( Suk Kyun Yang ),( Jeong Sik Byeon ),( Kyung Jo Kim ),( Byong Duk Ye ),( Sang Hyoung Park ),( Ta 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-

Background: Tumor necrosis factor antagonists are increasingly used to treat patients with immune-mediated inflammatory disease including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Because TNF-alpha is essential for the prevention of latent tuberculosis recrudescence, patients treated with TNF-alpha inhibitors are at increased risk of developing active TB. The time of initiating anti-TNF therapy following the induction of LTBI treatment is different depending on each nation’s guideline. We aimed to investigate the treatment outcome of patients with immune-mediated inflammatory disease who received anti- tumor necrosis factor therapy within 3 weeks of latent tuberculosis infection treatment. Methods: A total of 411 patients received LTBI treatment before commencing TNF antagonist between June 2004 and October 2013 at a tertiary referral center in South Korea. Their medical records were retrospectively reviewed. Results: The mean age of the 411 study subjects was 44.5 years and 261(63.5%) were male. The underlying IMID was ankylosing spondylitis in 203(49.4%), rheumatoid arthritis in 136(33.3%) and inflammatory bowel diseases in 57(13.9%) patients. Anti-TNF agent was initiated in 61 patients(14.8%) within 3 weeks after chemoprophylaxis for LTBI, whereas 3 weeks later in remaining 350 patients( 85.2%). These two groups were comparable in terms of baseline characteristics, treatment regimens, anti-TNF agents used and follow-up duration except significant difference of the mean duration of LTBI treatment before starting anti-TNF therapy(8 vs. 30 days, p < 0.001). A total of 6 patients developed TB during follow-up period. All of these patients received anti-TNF agents 3 weeks after initiation of LTBI treatment. None in the patients who commenced TNF antagonist within 3 weeks of LTBI treatment developed TB. Conclusions: The present study suggested that TNF antagonist may be initiated within 3 weeks of LTBI treatment in patients with IMID.

Preparation and Characterization of Antibacterial Cellulose Composite Film Using LiBr Solution

Ji-Wook Yang,Kyo-Jung Hwang,Sung-Yeol Kim,Gu-Joong Kwon,Dae-Young Kim 한국펄프·종이공학회 2016 한국펄프·종이공학회 학술발표논문집 Vol.2016 No.10

Poster Session : PS 1614 ; Mycobacterial Diseases : Initiation of Anti-TNF Therapy Within 3 Weeks of LTBI Treatment in Patients with Immune-Mediated Infl ammatory Diseases

( Ji Young Yang ),( Kyung Wook Jo ),( Seok Chan Hong ),( Bin Yoo ),( Chang Keun Lee ),( Yong Gil Kim ),( Suk Kyun Yang ),( Jeong Sik Byeon ),( Kyung Jo Kim ),( Byong Duk Ye ),( Sang Hyoung Park ),( Ta 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: Tumor necrosis factor antagonists are increasingly used to treat patients with immune-mediated infi ammatory disease including rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, and ulcerative colitis. Because TNF-alpha is essential for the prevention of latent tuberculosis recrudescence, patients treated with TNF-alpha inhibitors are at increased risk of developing active TB. The time of initiating anti-TNF therapy following the induction of LTBI treatment is different depending on each nation`s guideline. We aimed to investigate the treatment outcome of patients with immune-mediated infi ammatory disease who received anti-tumor necrosis factor therapy within 3 weeks of latent tuberculosis infection treatment. Methods: A total of 411 patients received LTBI treatment before commencing TNF antagonist between June 2004 and October 2013 at a tertiary referral center in South Korea. Their medical records were retrospectively reviewed. Results: The mean age of the 411 study subjects was 44.5 years and 261(63.5%) were male. The underlying IMID was ankylosing spondylitis in 203(49.4%), rheumatoid arthritisin 136(33.3%) and infi ammatory bowel diseases in 57(13.9%) patients. Anti-TNF agent was initiated in 61 patients(14.8%) within 3 weeks after chemoprophylaxis for LTBI, whereas 3 weeks later in remaining 350 patients(85.2%). These two groups were comparable in terms of baseline characteristics, treatment regimens, anti-TNF agents used and follow-up duration except signifi cant difference of the mean duration of LTBI treatment before starting anti-TNF therapy(8 vs. 30 days, p < 0.001). A total of 6 patients developed TB during follow-up period. All of these patients received anti-TNF agents 3 weeks after initiation of LTBI treatment. None in the patients who commenced TNF antagonist within 3 weeks of LTBI treatment developed TB. Conclusions: The present study suggested that TNF antagonist may be initiated within 3 weeks of LTBI treatment in patients with IMID.